Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Shift Work and Prostate Cancer Incidence in Industrial Workers: A Historical Cohort Study in a German Chemical Company.

Hammer GP, Emrich K, Nasterlack M, Blettner M, Yong M.

Dtsch Arztebl Int. 2015 Jul 6;112(27-28):463-70. doi: 10.3238/arztebl.2015.0463.

2.

Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study.

Bonberg N, Pesch B, Behrens T, Johnen G, Taeger D, Gawrych K, Schwentner C, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Oberlinner C, Stenzl A, Brüning T.

BMC Cancer. 2014 Nov 20;14:854. doi: 10.1186/1471-2407-14-854.

3.

A retrospective cohort study of shift work and risk of incident cancer among German male chemical workers.

Yong M, Blettner M, Emrich K, Nasterlack M, Oberlinner C, Hammer GP.

Scand J Work Environ Health. 2014 Sep;40(5):502-10. doi: 10.5271/sjweh.3438. Epub 2014 Jun 3.

4.

Shift work and risk of non-cancer mortality in a cohort of German male chemical workers.

Yong M, Nasterlack M, Germann C, Lang S, Oberlinner C.

Int Arch Occup Environ Health. 2014;87(7):763-73. doi: 10.1007/s00420-013-0922-5. Epub 2013 Dec 3.

PMID:
24297469
5.

Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.

Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäusser H, Kluckert M, Leng G, Nasterlack M, Lotan Y, Stenzl A, Brüning T; UroScreen Study Group.

Int Arch Occup Environ Health. 2014;87(7):715-24. doi: 10.1007/s00420-013-0916-3. Epub 2013 Oct 16.

PMID:
24129706
6.

A retrospective cohort study of shift work and risk of cancer-specific mortality in German male chemical workers.

Yong M, Nasterlack M, Messerer P, Oberlinner C, Lang S.

Int Arch Occup Environ Health. 2014 Feb;87(2):175-83. doi: 10.1007/s00420-013-0843-3. Epub 2013 Feb 3.

PMID:
23377535
7.

Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.

Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B; UroScreen Study Group.

BJU Int. 2013 Aug;112(4):E372-82. doi: 10.1111/j.1464-410X.2012.11666.x. Epub 2013 Jan 25.

8.

Occupational stress perception and its potential impact on work ability.

Yong M, Nasterlack M, Pluto RP, Lang S, Oberlinner C.

Work. 2013 Jan 1;46(3):347-54. doi: 10.3233/WOR-121556.

PMID:
23324708
9.

Shift work and cancer: state of science and practical consequences.

Yong M, Nasterlack M.

Arh Hig Rada Toksikol. 2012 Jun 1;63(2):153-60. doi: 10.2478/10004-1254-63-2012-2209. Review.

PMID:
22728797
10.

Worker protection during mercury electrolysis cell plant decommissioning.

Besson JC, Augarde E, Nasterlack M.

Arh Hig Rada Toksikol. 2012 Jun 1;63(2):117-22. doi: 10.2478/10004-1254-63-2012-2200.

PMID:
22728793
11.

Analysis of protein adducts as biomarkers of short-term exposure to ethylene oxide and results of follow-up biomonitoring.

Bader M, Will W, Frey G, Nasterlack M.

Arh Hig Rada Toksikol. 2012 Jun 1;63(2):107-15. doi: 10.2478/10004-1254-63-2012-2211.

PMID:
22728792
12.

Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.

Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A; UroScreen Study Group.

Urol Oncol. 2013 Nov;31(8):1656-62. doi: 10.1016/j.urolonc.2012.04.015. Epub 2012 May 22.

PMID:
22621963
13.

Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen.

Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, Kluckert M, Wellhäußer H, Eberle F, Nasterlack M, Leng G, Stenzl A, Brüning T; UroScreen Study Group.

PLoS One. 2012;7(4):e35363. doi: 10.1371/journal.pone.0035363. Epub 2012 Apr 16.

14.

Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A; UroScreen Study Group.

BJU Int. 2012 Sep;110(5):699-708. doi: 10.1111/j.1464-410X.2011.10883.x. Epub 2012 Feb 7.

15.

Exposure registries: overview and utility for nanomaterial workers.

Schulte PA, Mundt DJ, Nasterlack M, Mulloy KB, Mundt KA.

J Occup Environ Med. 2011 Jun;53(6 Suppl):S42-7. doi: 10.1097/JOM.0b013e31821aebed.

PMID:
21654416
16.

Developing a registry of workers involved in nanotechnology: BASF experiences.

David RM, Nasterlack M, Engel S, Conner PR.

J Occup Environ Med. 2011 Jun;53(6 Suppl):S32-4. doi: 10.1097/JOM.0b013e31821ad73f.

PMID:
21654414
17.

Role of medical surveillance in risk management.

Nasterlack M.

J Occup Environ Med. 2011 Jun;53(6 Suppl):S18-21. doi: 10.1097/JOM.0b013e31821b1d54.

PMID:
21606849
18.

The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.

Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T; UroScreen Group.

BJU Int. 2011 Aug;108(4):546-52. doi: 10.1111/j.1464-410X.2010.09971.x. Epub 2011 Jan 11. Erratum in: BJU Int. 2011 Oct;108(7):1232.

19.

Is health, measured by work ability index, affected by 12-hour rotating shift schedules?

Yong M, Nasterlack M, Pluto RP, Elmerich K, Karl D, Knauth P.

Chronobiol Int. 2010 Jul;27(5):1135-48. doi: 10.3109/07420528.2010.490111.

PMID:
20636221
20.

Medical program for shift workers--impacts on chronic disease and mortality outcomes.

Oberlinner C, Ott MG, Nasterlack M, Yong M, Messerer P, Zober A, Lang S.

Scand J Work Environ Health. 2009 Jul;35(4):309-18. Epub 2009 May 27.

Supplemental Content

Loading ...
Support Center